A shorter trifluridine–tipiracil schedule matched the standard in bowel cancer

When bowel cancer has spread and has stopped responding to the standard chemotherapies, the options narrow quickly. One of the last ones is trifluridine–tipiracil, an oral chemotherapy sold as Lonsurf, usually given with the antibody bevacizumab. It works, modestly, but its conventional four-week cycle is hard on the bone marrow and the gut. A large Japanese trial published in The Lancet on 24 October asked whether a shorter, gentler schedule gives up any of the survival benefit [s1].

What the drug is, and the problem with it

Trifluridine–tipiracil (FTD–TPI) pairs a cytotoxic nucleoside, trifluridine, with tipiracil, which stops the body breaking the trifluridine down before it can act [s1]. The established regimen runs on a 28-day cycle: the drug is taken on days 1 to 5 and again on days 8 to 12, with bevacizumab on days 1 and 15 [s1]. That fortnight of dosing drives much of the toxicity — in particular neutropenia, a fall in the infection-fighting white cells — along with nausea and loss of appetite [s1].

A simplified 14-day schedule had been proposed to spread the burden less heavily: FTD–TPI on days 1 to 5 only, with bevacizumab on day 1 [s1]. The open question was whether cutting the dose days this way would also cut the survival benefit.

How the trial was built

PRABITAS was a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial run across 178 hospitals in Japan, registered as jRCTs041230120 [s1][s2]. "Pragmatic" is the operative word: the eligibility criteria were deliberately broadened beyond those of conventional explanatory trials, and the procedures were aligned with routine clinical practice, so the population looks more like the patients a general oncology clinic actually sees [s1].

Between 26 December 2023 and 20 May 2025 the investigators randomly assigned 972 patients, 970 of whom made up the intention-to-treat population after two were excluded for being randomised before their site had approval [s1]. The groups split evenly — 486 to the conventional 28-day schedule and 484 to the 14-day schedule [s1]. The primary endpoint was overall survival, with a prespecified non-inferiority margin of 1.25 on the hazard ratio [s1]. That margin is the threshold the shorter schedule had to stay under to be judged "not meaningfully worse".

What it found

Over a median follow-up of 17.9 months, the two schedules were, on survival, indistinguishable [s1]. Median overall survival was 10.3 months (95% CI 9.5–11.6) with the conventional 28-day schedule and 11.3 months (95% CI 10.2–12.5) with the 14-day schedule, giving a stratified hazard ratio of 0.93 (95% CI 0.80–1.08) [s1]. Because the upper bound of that interval, 1.08, sits well below the 1.25 margin, the shorter schedule met the bar for non-inferiority [s1]. Survival at 12 months was 44.0% on the 28-day schedule and 47.5% on the 14-day schedule [s1].

The difference showed up where it was meant to, in the side effects. Grade 3 or worse neutropenia — the severe end, the kind that forces dose delays and raises infection risk — occurred in 13% of patients on the 14-day schedule against 39% on the conventional one, an absolute reduction of 25 percentage points (95% CI 20–31) [s1]. Grade 2 or worse anorexia fell from 26% to 15%, an 11-point reduction (95% CI 6–16) [s1].

What is, and is not, established

What PRABITAS supports is narrow and useful: in refractory metastatic colorectal cancer, giving FTD–TPI plus bevacizumab on a 14-day rather than a 28-day cycle preserves overall survival while roughly halving the rate of severe neutropenia and cutting appetite loss [s1]. For a treatment given late in the disease, where the aim is to buy time without wrecking quality of life, less toxicity for the same survival is a genuine gain.

The limits are worth stating. This was an open-label trial — patients and doctors knew which schedule they were on — which can colour the reporting of subjective symptoms, though not overall survival [s1]. It was conducted entirely in Japan, and whether the findings transfer cleanly to other populations and health systems is not something a single-country trial can answer [s1]. And "non-inferior" is not "better": the shorter schedule did not extend life, it matched it. Two treatment-related deaths occurred in the 14-day group and none in the 28-day group, a reminder that even a gentler schedule of cytotoxic chemotherapy is not without risk [s1].

Red flags: anyone on this chemotherapy who develops a fever, chills, a sore throat or other signs of infection should contact their oncology team urgently, because these can signal dangerously low white cells. This article describes research and is not medical advice. How and whether to dose this combination is a decision for patients and their treating oncologists.